secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001213900-24-113561
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies announces $6M private placement; OST-HER2 Phase 2b data in Jan 2025
--------------------------------------------------------------------------------

- Gross proceeds of $6M from sale of 1.5M units at $4.00/unit; each unit = 1 share Series A convertible preferred + 1 warrant.
- Initial conversion price $4.00, warrant exercise price $4.40; prices subject to reset with floor of $1.00 and ceiling $4.00.
- Proceeds to fund working capital and support commercialization of OST-HER2 for recurrent metastatic osteosarcoma.
- Phase 2b trial data for OST-HER2 expected during week of JP Morgan Healthcare Conference in January 2025.
- 95% of investment from pre-IPO and/or IPO investors; $6M provides cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/0001213900-24-113561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea0226258-8k_osthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-113561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer